Keryx Biopharmaceuticals, Inc. (KERX) Posts Q3 Loss of $0.15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts KERX Hot Sheet
Price: $3.36 --0%
Financial Fact:
Total research and development: 8.67M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Financial Fact:
Total research and development: 8.67M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) reported Q3 EPS of ($0.15), $0.03 worse than the analyst estimate of ($0.12).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Verra Mobility (VRRM) Tops Q3 EPS by 10c ; Offers Guidance
- enVVeno Medical (NVNO) Misses Q3 EPS by 302c
- Federal Realty Inv. Trust (FRT) Tops Q3 EPS by 3c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
